WO2024126194A1 - Procédé d'obtention de squalène végétal - Google Patents

Procédé d'obtention de squalène végétal Download PDF

Info

Publication number
WO2024126194A1
WO2024126194A1 PCT/EP2023/084498 EP2023084498W WO2024126194A1 WO 2024126194 A1 WO2024126194 A1 WO 2024126194A1 EP 2023084498 W EP2023084498 W EP 2023084498W WO 2024126194 A1 WO2024126194 A1 WO 2024126194A1
Authority
WO
WIPO (PCT)
Prior art keywords
squalene
composition
content
preferred
diafiltration
Prior art date
Application number
PCT/EP2023/084498
Other languages
English (en)
Inventor
Andreas Jakob
Jochen Becker
Sebastian DETLEFSEN
Martin GLOBISCH
Marc SCHÄPERTÖNS
Jens Martin DREIMANN
Original Assignee
Evonik Operations Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evonik Operations Gmbh filed Critical Evonik Operations Gmbh
Publication of WO2024126194A1 publication Critical patent/WO2024126194A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C7/00—Purification; Separation; Use of additives
    • C07C7/005—Processes comprising at least two steps in series
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C7/00—Purification; Separation; Use of additives
    • C07C7/10—Purification; Separation; Use of additives by extraction, i.e. purification or separation of liquid hydrocarbons with the aid of liquids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C7/00—Purification; Separation; Use of additives
    • C07C7/144—Purification; Separation; Use of additives using membranes, e.g. selective permeation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles

Definitions

  • Process for the production of a squalene composition having an enriched squalene content, in particular of a pharmaceutical squalene composition, from a squalene comprising composition having a lower squalene content, in particular from a plant-based oil having a lower squalene content comprising the steps of i) providing a composition comprising squalene having a lower squalene content, ii) subjecting the squalene comprising composition having a lower squalene content to a purification step at a temperature below the boiling point of squalene, and obtaining a composition with an intermediate squalene content, and iii) performing a chromatography step with the composition with an intermediate squalene content, and iv) obtaining a squalene composition having the enriched squalene content.
  • objects of the invention are also a squalene composition having an enriched squalene content, in particular a pharmaceutical squalene composition, in particular a parenteral pharmaceutical composition, more preferred a vaccine and an oil-in water emulsion comprising a squalene composition.
  • squalene is used as vaccine adjuvants and pharmaceutical formulations.
  • squalene-containing oils from animal sources, such as shark liver are used as the starting raw material for squalene production, as described in WO 2011141819 A1.
  • This squalene is obtained in pharmaceutically pure quality through a distillation process.
  • a thermal distillation process always bears the risk of degradation or isomerisation of components due to thermal distillation and vaporisation of the squalene which is in contact with the internal surface of a distillation system.
  • Extractive as well as chromatographic purification techniques are described, but these are not sufficient to produce pharmaceutically pure squalene as it is required according to pharmacopeia’s.
  • Object of the invention was to develop a process that is able to furnish squalene with pharmaceutical purity. Furthermore, it was an object of the invention to reduce the energy input of the process and to reduce the amount of used organic solvents. In addition, object of the invention was to provide a process that is adapted to plant-based squalene sources. Moreover, a process shall be developed with reduced thermal stress applied on squalene.
  • a combined process was developed utilising a purification step at a lower temperature, in particular a temperature below the boiling point, which is not a chromatographic purification step and not a distillation step.
  • the purification step is a filtration step or a chemical extraction step.
  • a process forthe production of a squalene composition having an enriched squalene content wherein the process provides in particular a pharmaceutical squalene composition, from a squalene comprising composition having a lower squalene content, and optionally a squalene composition having an enriched squalene content obtainable by the process is provided, wherein the process comprising the steps of i) providing a composition comprising squalene having a lower squalene content, ii) subjecting the squalene comprising composition having a lower squalene content to a purification step at a temperature below the boiling point of squalene, in particular at a temperature below 100 °C optionally at a pressure from 0.01 to 100 bar, in particular below 75 °C, and optionally at a pressure from 0.01 to 10 bar, and obtaining an intermediate composition with a squalene content, and iii) performing a chromatography step
  • the squalene comprising composition having a lower squalene content is a plantbased oil having a lower squalene content. Below the boiling point means below 275 °C at 20 hPa or at a lower temperature at the corresponding reduced pressure.
  • the squalene composition having an enriched squalene content is a pharmaceutical squalene composition. It is particularly preferred that the squalene comprising composition having a lower squalene content is amaranth oil.
  • the ii) purification step comprises physical and/or chemical purification step below the boiling point of squalene, such as a filtration step and/or chemical extraction step, in particular a chemical extraction step with recycling of the extraction agent.
  • the filtration step is preferred a filtration step utilizing a membrane filtration.
  • a particularly preferred purification step comprises a diafiltration step and/or an extraction step, in particular the extraction step is a liquid-liquid extraction step and/or the extraction step comprising a fluid-extraction.
  • the process may comprise i) providing a composition comprising squalene having a lower squalene content having a squalene content of below 12 wt.-% of squalene, wherein the composition sums up to 100 wt.-%, and ii) subjecting the squalene comprising composition having a lower squalene to a purification step at a temperature below the boiling point of squalene, in particular at a temperature below 100 °C, preferred below 75 °C, optionally at a pressure from 0.01 to 100 bar, preferred at 0.01 to 1 bar, and obtaining an intermediate composition with a squalene content of a least 14 wt.- % squalene, wherein the intermediate composition sums up to 100 wt.-%, and iii) performing a chromatography step with the intermediate composition with a squalene content, and iv) obtaining a squalene composition having
  • the newly developed process allows squalene to be obtained on a purely plant-based vegetable basis.
  • amaranth oil with an average squalene content of 1 to 10 wt.% which is first enriched via diafiltration, in particular diananofiltration.
  • This process allows a drastic solvent reduction compared to chemical extraction methods.
  • the resulting squalene composition (intermediate composition) obtained from diafiltration comprises approximately a squalene content of about 20 to 50 wt.-%.
  • This intermediate composition is further enriched via a chromatography step and the isolated composition from a chromatography unit has preferably after the removal of the mobile phase pharmaceutical quality.
  • composition comprising the mobile phase or part of the mobile phase can be treated with an adsorbent, such as activated carbon or diatomaceous earth, and final removal of the mobile phase, in particular the solvent.
  • an adsorbent such as activated carbon or diatomaceous earth
  • the combination of extraction and chromatography can also be used.
  • This can be a fluid-extraction or liquid-liquid- extraction comprising on the one hand a solvent extraction and on the other hand a fluid extraction with CO2 extraction.
  • the combination of diafiltration, in particular diananofiltration, and chromatography significantly reduces the use of solvents compared to extraction and chromatography, since diafiltration based on nanofiltration membranes can be performed without the use of additional solvents, in particular without organic solvents. This leads to an environmentally friendly process using significantly less undesired organic solvents.
  • a particular preferred embodiment of the current process is that the solvents used as mobile phase and/or as extracting agent can be reused.
  • the used liquid alkanes in particular hexane, n-hexane, and cyclohexane, can be reused after they were evaporated form the compositions. It is preferred that more than 90 % of the liquid alkanes used as mobile phase and/or extraction agent can be reused in the process. Due to the reuse of the amount of solvent for a process the amount of solvent per annum can be reduced.
  • the first purification step is used to separate the fatty acid esters contained in squalene comprising composition having a lower squalene content, and partial separation of phytosterols contained.
  • squalene comprising composition having a lower squalene content
  • partial separation of phytosterols contained By the chromatography and optional activated carbon filtration during the second step, the remaining components are separated and squalene with high, pharmaceutical purity is obtained.
  • the term diafiltration or diananofiltration describes a membrane-based process in which the solvent and, depending on the application, some of the ingredients of a solution or suspension are exchanged.
  • the starting composition here squalene comprising composition having a lower squalene content, whose further components, especially oily components, are to be exchanged, is circulated from a feed vessel.
  • TMP transmembrane pressure
  • MWCO molecular wheigt cut off
  • Chromatography is a chemical-physical technique for a separation of a mixture into its components.
  • a mixture comprising the mentioned components is dissolved in a fluid solvent, e.g., in a fluid-extraction, in particular gas, according to the invention in CO2 or in a solvent as liquid-liquid- extraction.
  • a fluid solvent e.g., in a fluid-extraction, in particular gas
  • the fluid solvent or liquid hydrocarbon is called the mobile phase.
  • the mobile phase carries the components through a system, like a column, a capillary tube, a plate, or a sheet, on which a material called the stationary phase is fixed or comprises the stationary phase.
  • the components of the mixture tend to have different affinities to the stationary phase and are retained for different lengths of time depending on their interactions with its surface sites of the stationary phase, the components pass the stationary phase at different apparent velocities in the mobile fluid, causing them to separate.
  • the separation is based on the differential partitioning between the mobile and the stationary phases. Subtle differences in a compound's partition coefficient result in differential retention on the stationary phase and thus affect the separation.
  • the ii) purification step may comprise a membrane filtration step, in particular a membrane based diafiltration step.
  • the membrane is a silicone-based membrane, like polydimethylsiloxane, the membrane optionally further comprises a polyacrylonitrile layer and/or a polyethylene terephthalate layer.
  • the membrane preferably has a molecular weight cut-off (MWCO) of 200 to 700 g/mol, preferably 280 to 600 g/mol. As there is no standard procedure for the determination of MWCO, this value maybe obtained differently.
  • MWCO molecular weight cut-off
  • Ri is the rejection of a polystyrene of a certain molecular weight
  • c P ,i is the permeate concentration
  • CR is the retentate concentration of this polystyrene.
  • the molecular weight cut-off is then described by the molecular weight of the polystyrene which shows a rejection R of 0.9.
  • the extraction step may comprise a liquid-liquid extraction step, wherein the extraction agent is at least one liquid hydrocarbon and/or a mixture comprising at least two liquid hydrocarbons, in particular at least a liquid alkane.
  • the alkane or alkanes can be selected from linear alkanes, branched alkanes and/or cyclic alkanes, in particular the alkane is selected from alkanes comprising pentane, hexane, heptane, octane, nonane, decane, undecane and dodecane and as well as all of their isomers, most preferred are n-hexane, n-heptane, cyclohexane, cycloheptane and/or mixtures thereof.
  • the extraction step may comprise a fluid-extraction, wherein the extraction agent is CO2.
  • Liquid alkanes mean liquid at a temperature below 100 °C, in particular liquid at room temperature and 20 hPa
  • the purification step in particularthe extraction step, comprises a saponification step prior to the extraction step, preferred the liquid-liquid extraction step.
  • the saponification step comprises a) that the squalene comprising composition having a lower squalene content is contacted with an alkaline, in particular an alkaline solution in an organic solvent, in particular an alkaline solution of an alcohol, e.g., methanol, ethanol, propanol, and b) a mixture is obtained.
  • step c) wherein in step c) the in b) obtained mixture is treated at elevated temperature, in particular the mixture is stirred and/or heated to a temperature in the range of 30 to 80 °C, in particular from 50 to 70 °C, more preferred from 50 °C.
  • step d) the mixture may be cooled down and in step e) water is added, in particular distilled water.
  • step f) the mixture and the added water are heated to an elevated temperature, in particular to a temperature in the range of 30 to 80 °C, in particular from 50 to 70 °C, more preferred from 50 °C, and the mixture and water are treated with the extraction agent and a resulting mixture is obtained.
  • the g) resulting mixture is allowed to separate into a water phase and an organic phase comprising the extraction agent and squalene, the two phases are separated and optionally the water phase is again treated with the extraction agent and optionally step g) is repeated, and in particular organic phases comprising the extraction agent and squalene are obtained.
  • the obtained organic phases comprising the extraction agent and squalene are combined and optionally contacted with water, in particular with distilled water, i) the resulting mixture is allowed to separate into a water phase and an organic phase comprising the extraction agent and squalene.
  • the j) this organic phase comprising the extraction agent and squalene is again contacted with water, in particular with distilled water, k) the resulting mixture is allowed to separate into a water phase and an organic phase comprising the extraction agent and squalene.
  • the organic phase comprising the extraction agent and squalene obtained in step i) and/or k) is treated under vacuum and/or elevated temperature to remove the extraction agent and the intermediate composition with a squalene content is obtained.
  • step I) the organic phase comprising the extraction agent, in particular with a reduced content of extraction agent, m) is contacted with an adsorbent, in particular contacted with an adsorbent and stirred, and n) the adsorbent is removed from this organic phase comprising the extraction agent, in particular the adsorbent is filtered off. And following, o) the organic phase comprising the extraction agent is treated under vacuum and/or elevated temperature to remove the extraction agent and the intermediate composition with a squalene content is obtained.
  • a preferred adsorbent is diatomaceous earth or activated charcoal.
  • the treatment under vacuum and/or elevated temperature may comprise treatment at a pressure from 0.1 mbar to below 1 bar, preferred in the range from 10 mbar to 600 mbar, more preferred from 100 mbar to 300 bar and in particular at a temperature in the range from room temperature to 60 °C, preferred in the range from 30 to 50 °C.
  • the chromatography step may be performed with a stationary phase comprising silica, alumina, diol functionalised polymers or diol functionalised silica and/or hydroxyl apatite, in particularthe stationary phase is selected from silica, alumina, diol functionalised polymers or diol functionalised silica and/or hydroxyl apatite.
  • the chromatography step may be performed with the intermediate composition with a squalene content and optionally with the addition of a mobile phase, and after evaporation of the mobile phase a squalene composition having the enriched squalene content may be obtained.
  • iii) performing a chromatography step with the intermediate composition with a squalene content
  • the step is performed with a mobile phase, in particular with the intermediate composition and a mobile phase. Therefore, iii) may be performed with the intermediate composition and an added mobile phase.
  • the chromatography step may be performed with a mobile phase comprising at least one liquid hydrocarbon, in particular at least one liquid alkane, preferred the at least one or more alkanes are selected from alkanes comprising pentane, hexane, heptane, octane, nonane, decane, undecane and dodecane, most preferred is cyclohexane.
  • the mobile phase can also be selected from a fluid solvent such as supercritical CO2.
  • the liquid phase comprises the composition comprising the intermediate composition with a squalene content and a liquid alkane, in particular as mobile phase, wherein the content of the intermediate composition with a squalene content is from 1 to 80 wt.-%, preferably from 5 to 30 wt.- % and the remaining is a mobile phase, in particular at least one liquid alkane, up to 100 wt.-% of the mobile phase.
  • the liquid alkane is in particular cyclohexane.
  • the liquid alkanes may comprise the above-mentioned liquid alkanes and or mixtures of at least two of them. Most preferred is cyclohexane, n-hexane, n-heptane, cycloheptane and/or mixtures thereof.
  • At least one additional step may comprise contacting the composition obtained from the chromatography step with at least one adsorbent, in particular the at least one adsorbent may comprise activated carbon, diatomaceous earth, silica and/or mixtures of at least two of them.
  • the squalene comprising composition having a lower squalene content may have a squalene content of below 12 wt.-% of squalene, in particular from 0.1 wt.-% to equal or below 10 wt.-%, preferably from 5 wt.-% to equal or below 10 wt.-%, wherein the composition sums up to 100 wt.-%, and/or b) the intermediate composition with a squalene content may have a squalene content of at least 14 wt.-% squalene, in particular equal or above 15 wt.-% to 90 wt.-%, preferably equal or above 15 wt.- % to 40 wt.-%, wherein the intermediate composition sums up to 100 wt.-%, and/or c) the squalene composition having the enriched squalene content, in particular a pharmaceutical squal
  • Another embodiment of the invention may comprise the diafiltration step, in particular the diafiltration step may comprise a membrane filtration step, and the membrane filtration step may be performed in a system comprising a feed vessel and at least one diafiltration apparatus, which is supplied with a feed, wherein the feed is the squalene comprising composition having a lower squalene content, in particular wherein the diafiltration apparatus comprises a membrane, preferred a nanofiltrationmembrane, and wherein from the at least one diafiltration apparatus a retentate, in particular at least one retentate, is obtained which is recycled to the feed vessel and from the at least one diafiltration apparatus a permeate, in particular at least one permeate, is obtained, wherein the permeate is the intermediate composition with a squalene content.
  • the diafiltration step is preferably performed continuously in a closed system.
  • the feed vessel possesses preferably a pressure of 100 mbar, which is obtained by using an inert gas atmosphere, preferably nitrogen.
  • the membrane is a silicon-based membrane, like polydimethylsiloxane, the membrane optionally further comprises a polyacrylonitrile layer and/or a polyethylene terephthalate layer.
  • the membrane preferably has a molecular weight cut-off (MWCO) of 200 to 700 g/mol, preferably 280 to 600 g/mol. The molecular weight cut-off is measured as described above.
  • At least one of the steps of the process of the invention is performed under an inert atmosphere, in particular under nitrogen, argon and/or a mixture of both.
  • the diafiltration step is performed under inert atmosphere.
  • the diafiltration apparatus is preferably supplied with a feed having an elevated temperature, in particular the feed, in particular the squalene comprising composition having a lower squalene content, having a temperature from 25 °C to below boiling temperature, in particular from 25 to 90 °C, preferred from 30°C to 70°C, most preferred from 30 to 60 °C or 50°C, and/or the feed is supplied under a pressure equal or above 1 bar to 100 bar, in particular above 20 bar, more preferred above 50 bar.
  • the pressure in the diafiltration apparatus in particular the pressure lay on the at least one membrane, is in the range from 10 to 100 bar, preferred in the range from 30 to 80 bar, more preferred from 50 to 70 bar, most preferred about 60 bar with +/- 5 bar.
  • the at least one permeate obtained from the at least one diafiltration apparatus comprises at least three diafiltration apparatuses that are combined after another in a series connection or are combined parallel in a series connection.
  • the first permeate resulting from the first diafiltration apparatus may be fed into the second diafiltration apparatus, wherein the permeate resulting from the second diafiltration apparatus is the intermediate composition with a squalene content.
  • the retentates form the at least two diafiltration apparatuses, in particularthe first and second diafiltration, are fed into the feed vessel.
  • the diafiltration step is preferably performed continuously in a closed system.
  • the apparatus and/or the process may be performed with 1 or 2 to 100 diafiltration apparatuses.
  • the squalene comprising composition having a lower squalene content may be in a particular preferred embodiment a plant-based squalene comprising composition, preferred are plant-based squalene comprising compositions with a squalene content from 1 to 14 wt.-%, preferred from 2 to 12 wt.-%, more preferred from 5 to 10 wt.-%. Most preferred as the squalene comprising composition having a lower squalene content are plant-based oils.
  • Plantbased oils that can be used comprise soybean oil, rice bran oil, olive oil, vegetable oils, in particular distillates of vegetable oils, coffee oil, wheat germ oil, corn germ oil, palm oil, andiroba oil, oil from tomato residues and amaranth oil. Most preferred is amaranth oil, in particular amaranth oil with a squalene content from 1 to 10 wt.-%, more preferred from 5 to 9 wt.-%.
  • a squalene composition can be used having a squalene content of up to 25 wt.-%.
  • the squalene composition needs to be enriched beforehand with an additional process step not claimed in the present application, thus contents of below 12 wt.-% are preferred.
  • a squalene composition having an enriched squalene content prepared according to the process of the invention is an embodiment of the invention.
  • the squalene composition is preferably a pharmaceutical squalene composition.
  • an embodiment of the invention is also a pharmaceutical composition comprising a squalene composition, preferred is a pharmaceutical squalene composition, in particular a parenteral composition, more preferred a vaccine.
  • the method is preferably performed in an apparatus that may comprise at least one feed vessel and at least one diafiltration apparatus, in particular for performing step ii) of the process, in particular the diafiltration apparatus may comprise a membrane, preferred a nanofiltration-membrane, more preferred a flat nanofiltration-membrane, wherein the at least one diafiltration apparatus is suppliable with a feed, wherein the feed is the squalene comprising composition having a lower squalene content, in particular according to the process of the invention, and wherein from the at least one diafiltration apparatus a retentate is obtainable which is recyclable to the feed vessel and a permeate is obtainable, wherein the permeate is the intermediate composition with a squalene content.
  • the flat membrane may have an area in one plane from 1 cm 2 to 1 m 2 , preferred from 10 cm 2 to 100 cm 2 .
  • the apparatus is preferably a closed system, wherein in the feed vessel the composition having a lower squalene content is supplied and from the at least one diafiltration apparatus a permeate is obtainable, wherein the permeate is the intermediate composition with a squalene content.
  • the squalene content is preferred from 10 to 80 wt.-%, more preferred from 20 to 80 wt.-%.
  • the feed vessel possesses preferably a pressure of at least 100 mbar at room temperature, which is obtained by using an inert atmosphere, preferably nitrogen.
  • GC gas chromatography
  • Type of injector Split/ split less for capillary columns
  • Amaranth-oil (educt, squalene content 5 to 10 wt.-%): GC analysis: 6.1 area%
  • Amaranth-oil enriched (squalene content 15 to 40 wt.-%): GC analysis: 20.2 area% squalene isolated (squalene content 97 to 99 wt.-%): GC analysis: 99.8 area%
  • Squalene-molecule Boiling point: 275 °C at 20 hPa
  • the nano-filtration was performed as described below according to figure 2.
  • Example 3A Chromatography after diafiltration with a nanofiltration-membrane
  • permeate obtained as permeate 2 was prepared as a 25 wt.-% of a squalene solution in cyclohexane and was chromatographed at 30 mL/min (Biichi Pure C-815, 50 mL syringe, UV detectors as mentioned below) over a cartridge (Biotage SNAP KP-Sil 50 g). The cartridge was conditioned with ethyl acetate for 6.47 min at a flow of 15 mL/min, followed by cyclohexane washing for 22.64 min at 15 mL/min. 30 mL of the 25 wt.-% squalene solution (permeate 2) was applied with the syringe onto the cartridge.
  • Example 3B Chromatography after diafiltration with a nanofiltration-membrane
  • Flash chromatography (Biichi C-815, cartridge: Biotage SNAP KP-Sil 50 g, UV detectors as mentioned below). Passivation was performed with 2 BV (bedvolume) ethyl acetate for 6.47 min (Flow 30 mL/min) and equilibration was performed with 6.99 BV cyclohexane.
  • the mixture was heated to 50 to 55 °C and extracted with 500 mL hexane, optionally GC analytic.
  • the hexane phase was separated and the water phase was extracted at 50 to 55 °C with 500 mL hexane.
  • the hexane phase was separated and combined with the first hexane phase at 50 to 55 °C and washed with demineralized 150 mL water.
  • the hexane from the separated hexane phase was removed in a rotary evaporator at 45 °C at 300 mbar to 10 mbar (Crude product: 3.51 g).
  • the obtained product (3.71 g product) was dissolved in 25 mL n-hexane and stirred for 30 min. The solvent was evaporated at the rotary evaporator and a creamy solid obtained which was dissolved in 25 mL cyclohexane and stirred for 30 min with 2.5 g silica (Porocell silica). The 25 wt.-% solution was filtered over a strainer (No. 4) and washed with cyclohexane. The filtrate was evaporated with a rotary evaporator and a clear, yellow solution obtained (oily).
  • Example 5 Chromatography (30 mL/min) of enriched amaranth oil (Flavex amaranth seed, 15 wt.-%) CO2 extracted
  • Flavex was mixed with 17 g cylohexane to obtain a yellow solution of 25 wt.-%. The mixture was stirred for 10 minutes with a magnetic stirrer. A slight yellow clear solution was obtained.
  • the cartridge was equilibrated with 3.5 BV cyclohexane for 22.6 min. Following the above obtained solution was injected to the cartridge (24 mL, application time: 0:48 min). 1 mL was used for gas chromatography.
  • Fig. 1 describes one alternative of the process disclosing the possible squalene content enrichment in the steps of the process.
  • Fig. 2 describes an apparatus 1 comprising the diafiltration apparatus 3.
  • Fig. 1 is a schematic overview of the process starting form a plant-base amaranth-oil with a typical squalene content from 5 to 10 wt.-% in the composition amounting to 100 wt.-%. Afterthe diafiltration step performed as nanofiltration step an intermediate composition with a squalene content of 15 to 40 wt.-% is obtained, wherein the composition amounts to
  • composition is subjected to a chromatography step, wherein the squalene composition having an enriched squalene content is obtained after the removal of the mobile phase.
  • adsorbent such as activated carbon
  • the step can be performed as a filtration step over activated carbon.
  • Fig. 2 describes the apparatus 1 comprising the diafiltration apparatus 3 for nano-filtration.
  • the tests were carried out in a continuously operating apparatus 1 see Fig. 2 in a closed circuit or with total return.
  • the apparatus 1 comprises a feed vessel 2 and a high-pressure circuit
  • the feed vessel 2 filled with amaranth oil (2 L) is overflowed with nitrogen and a slight overpressure due to the nitrogen of about 100 mbar is maintained.
  • the feed enters the high-pressure circuit 4 by means of a piston diaphragm pump, which is used for feeding the system.
  • the pressure of the circuit is regulated by means of an adjustable pre-pressure regulator up to 50 bar.
  • this circuit there is a flat channel test cell, in which the flat membrane to be tested with a flatness of 84.5 cm 2 is installed before the start of the test.
  • the built-in membrane (Silicone-coated PAN (Polyacrylnitril) PuraMem® Flux, Molecular Weight Cut off 280 to 600 g/mol) is overflowed in the circuit by means of a gear pump and the temperature of the circuit (30 to 60 °C) is controlled by a heat exchanger connected to an external thermostat and/or cryostat.
  • the apparatus 1 contains corresponding sensors such as pressure measurement and temperature measurement in the circuit 4.
  • sampling in the feed, retentate and permeate to determine the selectivity of the membrane.
  • the permeates are obtained in the flasks 5.
  • the components travel through the system in a closed circuit, so that constant conditions at the membrane are set for the most practicable measurement.
  • the permeate mass flow is determined selectively indirectly by balancing.
  • the permeance of the membrane can be obtained by dividing with the applied transmembrane pressure, which is the difference of the average pressure on the feed-side of the membrane ((PFeed+pRetentate)/2) and the pressure on the permeate side of the membrane (ppermeate) and the installed membrane area.
  • the intermediate composition with a squalene content of about 10 to 50 wt.-% in vessel is diluted with cyclohexane, wherein a 25 wt.-% solution is prepared in a downstream vessel with stir.
  • An apparatus for chromatography comprising at least one cartridge (SNAP KP-Sil 50 g) and a Biichi Pure C-815 flash system are used for chromatographic purification.
  • the cartridge is preconditioned with ethyl acetate (15 mL/min) and washed with cyclohexane (22 min at 15mL/min).
  • the sample submission is carried out with a 50 ml syringe. 30 ml samples of the 25% solution are applied to the chromatography column.
  • an additional step may comprise contacting the squalene composition with enriched squalene content and the mobile phase or at least a part of the mobile phase in a vessel with an adsorbent like activated charcoal and obtaining after removal of the mobile phase the composition with enriched squalene content, in particular a pharmaceutical squalene composition in flask.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Water Supply & Treatment (AREA)
  • Analytical Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention concerne un procédé de production d'une composition de squalène ayant une teneur enrichie en squalène, en particulier une composition de squalène pharmaceutique, qui forme une composition comprenant du squalène ayant une teneur en squalène inférieure, plus particulièrement à partir d'une huile végétale ayant une teneur en squalène inférieure, comprenant les étapes consistant à i) fournir une composition comprenant du squalène ayant une teneur en squalène inférieure, ii) soumettre la composition comprenant du squalène ayant une teneur en squalène inférieure à une étape de purification à une température inférieure au point d'ébullition du squalène, et obtenir une composition intermédiaire ayant une teneur en squalène, et iii) effectuer une étape de chromatographie avec la composition intermédiaire ayant une teneur en squalène, et iv) obtenir une composition de squalène ayant la teneur en squalène enrichie. En outre, des objets de l'invention concernent également une composition de squalène ayant une teneur enrichie en squalène, en particulier une composition pharmaceutique de squalène, plus particulièrement une composition pharmaceutique parentérale, de préférence encore un vaccin et une émulsion huile-dans-eau comprenant une composition de squalène.
PCT/EP2023/084498 2022-12-12 2023-12-06 Procédé d'obtention de squalène végétal WO2024126194A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22212696.3 2022-12-12
EP22212696 2022-12-12

Publications (1)

Publication Number Publication Date
WO2024126194A1 true WO2024126194A1 (fr) 2024-06-20

Family

ID=84785305

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2023/084498 WO2024126194A1 (fr) 2022-12-12 2023-12-06 Procédé d'obtention de squalène végétal

Country Status (1)

Country Link
WO (1) WO2024126194A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008056263A2 (fr) * 2006-11-08 2008-05-15 Novartis Ag Méthodes de contrôle qualité pour des émulsions d'huile dans l'eau contenant du squalène
WO2011141819A1 (fr) 2010-05-12 2011-11-17 Novartis Ag Procédés améliorés d'élaboration de squalène
WO2012169443A1 (fr) * 2011-06-06 2012-12-13 Ｊｘ日鉱日石エネルギー株式会社 Procédé de fabrication de squalène végétal raffiné et squalène végétal raffiné
CN105367370A (zh) * 2014-08-27 2016-03-02 浙江医药股份有限公司新昌制药厂 一种从提取天然维生素e后的脚料中提取角鲨烯的方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008056263A2 (fr) * 2006-11-08 2008-05-15 Novartis Ag Méthodes de contrôle qualité pour des émulsions d'huile dans l'eau contenant du squalène
WO2011141819A1 (fr) 2010-05-12 2011-11-17 Novartis Ag Procédés améliorés d'élaboration de squalène
WO2012169443A1 (fr) * 2011-06-06 2012-12-13 Ｊｘ日鉱日石エネルギー株式会社 Procédé de fabrication de squalène végétal raffiné et squalène végétal raffiné
CN105367370A (zh) * 2014-08-27 2016-03-02 浙江医药股份有限公司新昌制药厂 一种从提取天然维生素e后的脚料中提取角鲨烯的方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
M. AZALIA LOZANO-GRANDE ET AL.: "Plant Sources, Extraction Methods, and Uses of Squalene", INTERNATIONAL JOURNAL OF AGRONOMY, vol. 2018, 2018, pages 13
NISARG GOHIL ET AL.: "Engineering Strategies in Microorganisms forthe Enhanced Production of Squalene: Advances, Challenges and Opportunities", FRONT. BIOENG. BIOTECHNOL, vol. 7, 2019
PARK JAEHYUN ET AL: "Microbial Bioprocess for Extracellular Squalene Production and Formulation of Nanoemulsions", ACS SUSTAINABLE CHEMISTRY & ENGINEERING, vol. 9, no. 42, 8 October 2021 (2021-10-08), US, pages 14263 - 14276, XP093050583, ISSN: 2168-0485, DOI: 10.1021/acssuschemeng.1c05453 *
PH. EUR., pages 01 - 2020,2805

Similar Documents

Publication Publication Date Title
EP3978095A1 (fr) Chromatographie de partition cpc de cannabinoïdes
EP1443036B2 (fr) Procede de production d'alcanolamines a haute purete
DD222301A5 (de) Verfahren zur gewinnung von hochreinem 1-buten
JPS5950277B2 (ja) 粗製グリセリド油組成物の精製方法
EP0399193B1 (fr) Distillation extractive d'hydrocarbures à l'aide d'un mélange de solvants
CA2129118A1 (fr) Separation supercritique d'isomeres de composes organiques fonctionnels sous des conditions moderees
CN114901622A (zh) 1,3-丁二醇的制造方法以及1,3-丁二醇制品
US11306339B2 (en) Method for the production of a rhamnolipid
AU2020344019A1 (en) Method for simultaneously separating cannabidivarin and cannabigerol
WO2024126194A1 (fr) Procédé d'obtention de squalène végétal
US20040254407A1 (en) 1, 3-butylene glycol and process for producing the same
US10702795B2 (en) Process for high purity hexane and production thereof
CN105418575B (zh) 一种采用两步反萃取法提取天然维生素e的方法
CN106478339A (zh) 一种分离环戊烷和2,2-二甲基丁烷的方法
CN104744406B (zh) 利用重质松节油制备环氧石竹烯及分离长叶烯的方法
CA3132820A1 (fr) Solution de recuperation d'alcool et procede d'utilisation associe
Kim et al. Liquid membrane permeation of nitrogen heterocyclic compounds contained in model coal tar fraction
CN111978156A (zh) 一种制备大麻二酚的方法
EP2208724B1 (fr) Procédé pour la purification du latanoprost
EP0732589A3 (fr) Méthodes pour tester la tendence à l'encrassement des boues FCC
US2126600A (en) Separation of methylamines
US2609333A (en) Azeo-extractive distillation
CN114315546B (zh) 含水、丙二醇甲醚、环戊酮的废电子溶剂处理方法
JP7441358B1 (ja) ３，５，５－トリメチルヘキサン酸組成物
TW201819017A (zh) 2-烷氧基乙醇之去除或回收方法、及(2-烷氧基乙基)乙烯基醚之製造方法